Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanofi (SNY) Raw Materials (2016 - 2018)

Sanofi's Raw Materials history spans 4 years, with the latest figure at $1.2 billion for Q4 2018.

  • For Q4 2018, Raw Materials rose 2.38% year-over-year to $1.2 billion; the TTM value through Dec 2018 reached $1.2 billion, up 2.38%, while the annual FY2018 figure was $1.2 billion, 10.48% up from the prior year.
  • Raw Materials for Q4 2018 was $1.2 billion at Sanofi, up from $1.1 billion in the prior quarter.
  • Across five years, Raw Materials topped out at $1.2 billion in Q4 2018 and bottomed at $1.0 billion in Q4 2016.
  • The 4-year median for Raw Materials is $1.1 billion (2015), against an average of $1.1 billion.
  • The largest annual shift saw Raw Materials decreased 2.62% in 2016 before it rose 10.54% in 2017.
  • A 4-year view of Raw Materials shows it stood at $1.1 billion in 2015, then dropped by 2.62% to $1.0 billion in 2016, then grew by 10.54% to $1.1 billion in 2017, then rose by 2.38% to $1.2 billion in 2018.
  • Per Business Quant, the three most recent readings for SNY's Raw Materials are $1.2 billion (Q4 2018), $1.1 billion (Q4 2017), and $1.0 billion (Q4 2016).